Revolutionizing Drug Development and Diagnostics

By Ken Rubenstein, Ph.D.

Published: September, 2003

220+ Pages, 24 Exhibits, 24 Companies Profiled 

Post-genomic biomarker-based diagnostic products are projected to grow from $100 million in 2003 to $2 billion by 2008. 

Biomarkers are not new; certainly their use in pharmaceutical, diagnostic, and biomedical R&D goes back several decades. So why has there been so much activity recently? For most of the latter half of the twentieth century, the appearance of a new biomarker was a relatively rare event. The rise of new genomic, proteomic, and metabonomic technologies during the past decade has provided a major acceleration in the rate of biomarker discovery and major improvement in the quality and utility of the resulting markers. The availability of these new-wave markers provides pharmaceutical companies important new opportunities for improving the time- and cost-efficiency of drug development, as well as providing diagnostic companies access to new assays that promise vast improvement in early disease detection, prognosis, and monitoring.

D&MD's Post-Genomic Biomarkers: Revolutionizing Drug Development and Diagnostics Market Analysis Report provides deep insights into the evolution of this field, the technologies contributing to biomarker discovery and detection, emerging applications of new-wave biomarkers, and market trends. In addition, the Report presents a series of revealing interviews with key experts in this young and dynamic field, along with in-depth profiles of key companies contributing to the revolution. 

This Report Will Help You: 

Pinpoint the market potential of biomarkers with an examination of the projected market impact through 2008.

Determine the competitive advantage of classical versus post-genomic biomarker technologies for discovery and detection through a comprehensive breakdown of the capabilities and limitations of both.

Discover the commercial viability of biomarker technology platforms through a detailed breakdown of their widespread uses and applications.

Gain reliable and thought provoking insights into the biomarkers area from dynamic interviews with authorities involved in this industry.Look inside 24 companies working within the biomarker field-including strengths and weaknesses, product pipelines, alliances, business strategies, and more. 

Publisher: Drug and Market Development 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/DMD_2003.html#a55